{
 "@context" : "http://schema.org",
  "@id" : "http://bio2rdf.org/drugbank:DB00063",
  "@type" : "Drug",
  "administrationRoute" : "intravenous",
  "availableStrength" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:d22be43d19772ebee8285e121e900af9",
    "@type" : "DrugStrength",
    "description" : "0.75 mg Solution form with intravenous route"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:b9f61619a00a6c02f73eb60c5107544e",
    "@type" : "DrugStrength",
    "description" : "2 mg Solution form with intravenous route"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:61ecd29eb2276a23da72a14dd028a1ec",
    "@type" : "DrugStrength",
    "description" : "2 mg/mL Injection, solution form with intravenous route"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:6809f7354be48347bc1dfd6cc49dad48",
    "@type" : "DrugStrength",
    "description" : ".75 mg/mL Injection, solution form with intravenous route"
  } ],
  "clinicalPharmacology" : "Eptifibatide is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. Eptifibatide is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets.",
  "cost" : [ {
    "@id" : "http://bio2rdf.org/drugbank_resource:9fae1a37fef3cd521e45540cd00d56a9",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "10.739999771118164062",
    "drugUnit" : "Integrilin 200 mg/100 ml vial"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:017373958e6c3de9b55f77e9077674fd",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "3.8800001144409179688",
    "drugUnit" : "Integrilin 75 mg/100 ml vial"
  }, {
    "@id" : "http://bio2rdf.org/drugbank_resource:8d5581ce9c275060b6ffd1e8de4ba7d0",
    "@type" : "DrugCost",
    "costCurrency" : "USD",
    "costPerUnit" : "12.409999847412109375",
    "drugUnit" : "Integrilin 20 mg/10 ml vial"
  } ],
  "description" : "Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation.",
  "dosageForm" : [ "Injection, solution", "Solution" ],
  "drugClass" : "Platelet Aggregation Inhibitors",
  "identifier" : "drugbank:DB00063",
  "interactingDrug" : [ "DDI between Eptifibatide and Treprostinil - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Streptokinase - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Eptifibatide and Ethyl biscoumacetate - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Glucosamine - May enhance the antiplatelet effect of Agents with Antiplatelet Properties.", "DDI between Eptifibatide and Apixaban - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.", "DDI between Eptifibatide and Dicoumarol - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Enoxaparin - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Citric Acid - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Acetylsalicylic acid - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.", "DDI between Eptifibatide and Dalteparin - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Warfarin - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Reteplase and Eptifibatide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Eptifibatide and Pentoxifylline - May enhance the antiplatelet effect of Agents with Antiplatelet Properties.", "DDI between Eptifibatide and Obinutuzumab - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.", "DDI between Eptifibatide and Ridogrel - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Abciximab and Eptifibatide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Anistreplase and Eptifibatide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Eptifibatide and Vitamin E - May enhance the antiplatelet effect of Agents with Antiplatelet Properties.", "DDI between Alteplase and Eptifibatide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Eptifibatide and Salicylate-sodium - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.", "DDI between Tenecteplase and Eptifibatide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Eptifibatide and Edetic Acid - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Acenocoumarol - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Deoxycholic Acid - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased.", "DDI between Eptifibatide and Phenindione - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Urokinase and Eptifibatide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.", "DDI between Eptifibatide and Ibritumomab - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.", "DDI between Eptifibatide and Fondaparinux sodium - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Heparin - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Dasatinib - May enhance the anticoagulant effect of Agents with Antiplatelet Properties.", "DDI between Eptifibatide and Dabigatran etexilate - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.", "DDI between Eptifibatide and Tipranavir - May enhance the antiplatelet effect of Agents with Antiplatelet Properties.", "DDI between Eptifibatide and Phenprocoumon - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Sulodexide - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.", "DDI between Eptifibatide and Rivaroxaban - Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban." ],
  "legalStatus" : [ "Approved", "Investigational" ],
  "manufacturer" : {
    "@id" : "http://bio2rdf.org/drugbank_resource:69af0ec5fb5eed82637d863c4ec2736b",
    "@type" : "Organization",
    "name" : "Schering corp"
  },
  "mechanismOfAction" : "Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner.",
  "name" : "Eptifibatide",
  "nonProprietaryName" : [ "Integrelin", "Intrifiban" ],
  "sameAs" : [ "http://www.drugs.com/cdi/eptifibatide.html", "http://www.drugbank.ca/drugs/DB00063", "http://www.rxlist.com/cgi/generic/eptifibatide.htm" ],
  "url" : "https://schemaorg.metadatacenter.org/drugbank/DB00063.html"
}